Full Press Release Details
Water Vaccines Announces Pricing of approximate $20M Initial Public Offering
Feb. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. ("BWV" or "Blue Water Vaccines" or the "Company"),
a biopharmaceutical company developing vaccines, today announced the pricing of its initial public offering of 2,222,222 shares of its
common stock at a public offering price of $9.00 per share. The shares are expected to begin trading on the Nasdaq Capital
Market under the ticker symbol "BWV" on February 18, 2022.
aggregate gross proceeds to BWV from the initial public offering are expected to be approximately $20 million prior to deducting underwriting
discounts, commissions, and other estimated offering expenses. The offering is expected to close on February 23, 2022, subject to
the satisfaction of customary closing conditions.
Securities, LLC is acting as the sole book-running manager for the offering.
Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-1 relating to these securities
on February 11, 2022. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by
means of a prospectus, copies of which, when available, may be obtained from; Boustead Securities, LLC, Attention: Prospectus Department,
6 Venture, Suite 325, Irvine, CA 92618, or by telephone at 949-502-4408, or by email at offerings@boustead1828.com. Investors may also
obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information
about the Company and the offering.
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
Water Vaccines, Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges
globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University
of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal
flu vaccine that will provide protection from all virulent strains and a Streptococcus pneumoniae (pneumococcus) vaccine
candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.
Additionally, Blue Water Vaccines has licensed a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria among others. For
more information, visit www.bluewatervaccines.com.
Note Concerning Forward-Looking Statements
press release contains "forward-looking statements," including with respect to the initial public offering. No assurance
can be given that the offering discussed above will be completed on the terms described, or at all, or that the proceeds of the offering
will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the
Company, including those set forth in the Risk Factors section of the Company's registration statement for the initial public offering
filed with the SEC. Copies are available on the SEC's website, www.sec.gov. Although the Company believes that the expectations
reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does
not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the
date of this press release, except as required by law.